Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 5, 1997, Pages 1115-1123

  Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a   Ikebe, Masahiko ^a   Teicher, Beverly A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CD31 staining; Transforming growth factor ; Tumor hypoxia; Tumor oxygenation

Indexed keywords

CYCLOPHOSPHAMIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; FEMALE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR BLOOD FLOW;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL HYPOXIA; CYCLOPHOSPHAMIDE; ENDOTHELIAL GROWTH FACTORS; FEMALE; LYMPHOKINES; MAMMARY NEOPLASMS, EXPERIMENTAL; OXYGEN CONSUMPTION; RATS; RATS, INBRED F344; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030906260     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00573-1     Document Type: Article

References (42)

1. Anscher, M. S.; Jirtle, R. L. Role of transforming growth factor-β and hepatocyte growth factor in late normal tissue effects of radiation. Radiat. Oncol. Invest. 1:305-313; 1994.
2. Bauer, G. Resistance to TGF-β-induced elimination of transformed cells is required during tumor progression (Review-Hypothesis). Int. J. Oncol. 6:1227-1229; 1995.
3. Chatterjee, D.; Liu, J. T.; Northey, D.; Teicher, B. A. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother. Pharmacol. 35:423-431; 1995.
4. Dewey, W. C.; Ling, C. C.; Meyn, R. E. Radiation-induced apoptosis: Relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 33:781-796; 1995.
5. Dewhirst, M. W. Angiogenesis and blood flow. In: Teicher, B. A., ed. Drug resistance in oncology. New York: Marcel Dekker; 1993:3-24.
6. Fregene, T. A.; Khanuja, P. S.; Gimotty, P. A.; Kellogg, C.; George, J.; Pienta, K. J. The relationship of micro vessel counts to tumor size, estrogen receptor status, lymph node metastasis, and disease-free survival in patients with stage I and II breast cancer. Int. J. Oncol. 5:1437-1445; 1994.
7. Frei, E., III; Teicher, B. A.; Cucchi, C. A.; Rosowsky, A.; Flatow, J. L.; Kelley, M. J.; Genereux, P. Resistance to alkylating agents: Basic studies and therapeutic implications. In: Woolley, P. V. I.; Tew, K. D., eds. Mechanisms of drug resistance in neoplastic cells. New York: Academic Press; 1988:69-87.
8. Hall, E. J. Radiobiology for the radiobiologist, 2nd ed. Philadelphia: Harper & Row; 1978.
9. Hill, R. P. Sensitizers and radiation dose fractionation: Results and interpretations. Int. J. Radiat. Oncol. Biol. Phys. 12:1049-1054; 1986.
10. Horak, E. R.; Leek, R.; Klenk, N.; LeJeune, S.; Smith, K.; Stuard, N.; Greenall, M.; Stepniewska, K.; Harris, A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124; 1992.
11. Jain, R. K. Physiological resistance to the treatment of solid tumors. In: Teicher, B. A., ed. Drug resistance in oncology. New York: Marcel-Dekker; 1993:87-105.
12. Kaufmann, A. M.; Stoeck, M.; Schirrmacher, V.; Lichtner, R. B. Transforming growth factor-β production and induction of cellular responses in 13762NF rat mammary adenocarcinoma cell clones. Invasion Metastasis 13:244-252; 1993.
13. Kekow, J.; Wiedemann, G. J. Transforming growth factor β: A cytokine with multiple actions in oncology and potential clinical applications (review). Int. J. Oncol. 7:177-182; 1995.
14. Koch, A. E.; Harlow, L. A.; Haines, G. K.; Amento, E. P.; Unemori, E. N.; Wong, W. L.; Pope, R. M.; Ferrara, N. Vascular endothelial growth factor. J. Immunol. 152:4149-4156; 1994.
15. Levy, A. P.; Levy, N. S.; Wegner, S.; Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270:13333-13340; 1995.
16. McBride, W. H. Cytokine cascades in late normal tissue radiation responses. Int. J. Radiat. Oncol. Biol. Phys. 33:233-234; 1995.
17. Meyn, R. E.; Stephens, L. C.; Hunter, N. R.; Milas, L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother. Pharmacol. 33:410-414; 1994.
18. Miettinen, M.; Lindenmayer, A. E.; Chaubal, A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens: Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Modern Pathol. 7:82-90; 1994.
19. Mukhopadhyay, D.; Tsiokas, L.; Zhou, X.-M.; Foster, D.; Brugge, J. S.; Sukhatme, V. P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581; 1995.
20. Olive, P. L. Radiation-induced reoxygenation in the SCCVII murine tumour: Evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother. Oncol. 32:37-46; 1994.
21. Randall, K.; Coggle, J. E. Expression of transforming growth factor-β1 in mouse skin during the acute phase of radiation damage. Int. J. Radiat. Biol. 68:301-309; 1995.
22. Rodemann, H. P.; Bamberg, M. Cellular basis of radiation-induced fibrosis. Radiother. Oncol. 35:83-90; 1995.
23. Rubin, P.; Johnston, C. J.; Williams, J. P.; McDonald, S.; Finkelstein, J. N. A perpetual cascade of cytokines postir-radiation leads to pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 33:99-109; 1995.
24. Sakaguchi, Y.; Stephens, L. C.; Makino, M.; Kaneko, T.; Strebel, F. R.; Danhauser, L. L.; Jenkins, G. N.; Bull, J. M. C. Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Res. 55:5459-5464; 1995.
25. Samuel, S. K.; Hurta, R. A. R.; Kondaiah, P.; Khalil, N.; Turley, E. A.; Wright, J. A.; Greenberg, A. H. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-β1 (Ser223, 225). EMBO J. 11:1599-1605; 1992.
26. Senger, D. R.; Van De Water, L.; Brown, L. F.; Nagy, J. A.; Yeo, K.-T.; Yeo, T.-K.; Berse, B.; Jackman, R. W.; Dvorak, A. M.; Dvorak, H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303-324; 1993.
27. Song, C. W.; Lyons, J. C.; Luo, Y. Intra- and extracellular pH in solid tumors: Influence on therapeutic response. In: Teicher, B. A., ed. Drug resistance in oncology. New York: Marcel Dekker, Inc.; 1992:25-51.
28. Stephens, L. C.; Hunter, N. R.; Ang, K. K.; Milas, L.; Meyn, R. E. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat. Res. 135:75-80; 1993.
29. Teicher, B. A. In vivo resistance to antitumor alkylating agents. In: Teicher, B. A., ed. Drug resistance in oncology. New York: Marcel Dekker, Inc.; 1993:263-290.
30. Teicher, B. A. Physiologic mechanisms of therapeutic resistance: Blood flow and hypoxia. In: Fisher, G., ed. Hematology/oncology clinics of North America, drug resistance in clinical oncology and hematology. Philadelphia, PA: W. B. Saunders Co.; 1995:475-506.
31. Teicher, B. A.; Chatterjee, D.; Liu, J.-T.; Holden, S. A.; Ara, G. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother. Pharmacol. 32:315-319; 1993.
32. Teicher, B. A.; Dupuis, N. P.; Holden, S. A.; Schwartz, G. N.; Lester, S.; Frei, E., III. Definition and manipulation of tumor oxygenation. Radiat. Oncol. Invest. 2:66-76; 1994.
33. Teicher, B. A.; Dupuis, N. P.; Kusumoto, T.; Liu, M.; Liu, F.; Menon, K.; Schwartz, G. N.; Frei, E., III. Decreased tumor oxygenation after cyclophosphamide reoxygenation and therapeutic enhancement with a perflubron emulsion/carbogen breathing. Int. J. Oncol. 3:197-203; 1993.
34. Teicher, B. A.; Dupuis, N. P.; Robinson, M. F.; Kusumoto, T.; Liu, M.; Menon, K. Reduced oxygenation in a rat mammary carcinoma post-radiation and reoxygenation with a perflubron emulsion/carbogen breathing. In Vivo 8:125-132; 1994.
35. Teicher, B. A.; Frei, E., III. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol. 21:292-298; 1988.
36. Teicher, B. A.; Herman, T. S.; Holden, S. A.; Wang, Y.; Pfeffer, M. R.; Crawford, J. M.; Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457-1461; 1990.
37. Teicher, B. A.; Holden, S. A.; Ara, G.; Chen, G. Transforming growth factor-β in in vivo resistance. Cancer Chemother. Pharmacol. 37:601-609; 1996.
38. Teicher, B. A.; Holden, S. A.; Ara, G.; Dupuis, N.; Goff, D. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Cancer J. Sci. Am. 1:43-48; 1995.
39. Teicher, B. A.; Holden, S. A.; Herman, T. S.; Alvarez Sotomayor, E.; Khandekar, V.; Rosbe, K. W.; Brann, T. W.; Korbut, T. T.; Frei, E., III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer 47:252-260; 1991.
40. Teicher, B. A.; Holden, S. A.; Jacobs, J. L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res. 47:513-518; 1987.
41. Teicher, B. A.; Holden, S. A.; Rose, C. M. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing. Int. J. Cancer 36:585-589; 1985.
42. Vaupel, P. Oxygenation of solid tumors. In: Teicher, B. A., ed. Drug resistance in oncology. New York: Marcel-Dekker; 1993:53-85.